261 related articles for article (PubMed ID: 22268497)
1. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
[TBL] [Abstract][Full Text] [Related]
2. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
4. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
McGill JB; Barnett AH; Lewin AJ; Patel S; Neubacher D; von Eynatten M; Woerle HJ
Diab Vasc Dis Res; 2014 Jan; 11(1):34-40. PubMed ID: 24169807
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
16. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
